# Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum

> **NCT03308357** · — · UNKNOWN · sponsor: **The Alfred** · enrollment: 6 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DIAGNOSTIC_TEST:** Drug assays to measure infliximab

## Key facts

- **NCT ID:** NCT03308357
- **Lead sponsor:** The Alfred
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2017-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03308357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03308357, "Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03308357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*